238 related articles for article (PubMed ID: 33850556)
1. Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway.
Yang L; Li J; Li Y; Zhou Y; Wang Z; Zhang D; Liu J; Zhang X
Exp Ther Med; 2021 Jun; 21(6):584. PubMed ID: 33850556
[TBL] [Abstract][Full Text] [Related]
2. 3-Bromopyruvic acid regulates glucose metabolism by targeting the c-Myc/TXNIP axis and induces mitochondria-mediated apoptosis in TNBC cells.
Li J; Pan J; Liu Y; Luo X; Yang C; Xiao W; Li Q; Yang L; Zhang X
Exp Ther Med; 2022 Aug; 24(2):520. PubMed ID: 35837063
[TBL] [Abstract][Full Text] [Related]
3. 3-Bromopyruvate Inhibits the Growth and Glucose Metabolism of TNBC Xenografts in Nude Mice by Targeting c-Myc.
Pan JM; Li JC; Yang C; Xiao WF; Li QS; Luo XH; Zhang XD
Anticancer Agents Med Chem; 2023; 23(12):1421-1428. PubMed ID: 37038711
[TBL] [Abstract][Full Text] [Related]
4. New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells.
Gottfried E; Lang SA; Renner K; Bosserhoff A; Gronwald W; Rehli M; Einhell S; Gedig I; Singer K; Seilbeck A; Mackensen A; Grauer O; Hau P; Dettmer K; Andreesen R; Oefner PJ; Kreutz M
PLoS One; 2013; 8(7):e66987. PubMed ID: 23874405
[TBL] [Abstract][Full Text] [Related]
5. Physciosporin suppresses mitochondrial respiration, aerobic glycolysis, and tumorigenesis in breast cancer.
Taş İ; Varlı M; Son Y; Han J; Kwak D; Yang Y; Zhou R; Gamage CDB; Pulat S; Park SY; Yu YH; Moon KS; Lee KH; Ha HH; Hur JS; Kim H
Phytomedicine; 2021 Oct; 91():153674. PubMed ID: 34333327
[TBL] [Abstract][Full Text] [Related]
6. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
[TBL] [Abstract][Full Text] [Related]
7. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
8. 2-Methoxy-1,4-Naphthoquinone (MNQ) Inhibits Glucose Uptake and Lactate Production in Triple-Negative Breast Cancer Cells.
Daud SM; Yaacob NS; Fauzi AN
Asian Pac J Cancer Prev; 2021 Feb; 22(S1):59-65. PubMed ID: 33576213
[TBL] [Abstract][Full Text] [Related]
9. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Wu Q; Ba-Alawi W; Deblois G; Cruickshank J; Duan S; Lima-Fernandes E; Haight J; Tonekaboni SAM; Fortier AM; Kuasne H; McKee TD; Mahmoud H; Kushida M; Cameron S; Dogan-Artun N; Chen W; Nie Y; Zhang LX; Vellanki RN; Zhou S; Prinos P; Wouters BG; Dirks PB; Done SJ; Park M; Cescon DW; Haibe-Kains B; Lupien M; Arrowsmith CH
Nat Commun; 2020 Aug; 11(1):4205. PubMed ID: 32826891
[TBL] [Abstract][Full Text] [Related]
10. Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
Shi Y; Zhang Y; Ran F; Liu J; Lin J; Hao X; Ding L; Ye Q
Cancer Lett; 2020 Dec; 495():53-65. PubMed ID: 32946964
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of OLR1 weakens glycolytic metabolism to repress colon cancer cell proliferation and chemoresistance by downregulating SULT2B1 via c-MYC.
Zhao T; Li Y; Shen K; Wang Q; Zhang J
Cell Death Dis; 2021 Dec; 13(1):4. PubMed ID: 34921134
[TBL] [Abstract][Full Text] [Related]
14. Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer.
Liu Z; Cheng S; Fu G; Ji F; Wang C; Cao M
Life Sci; 2020 Jun; 251():117604. PubMed ID: 32243929
[TBL] [Abstract][Full Text] [Related]
15. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
16. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
17. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
18. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
19. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
Hu MH; Wu TY; Huang Q; Jin G
Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
[TBL] [Abstract][Full Text] [Related]
20. NOX4-derived ROS Regulates Aerobic Glycolysis of Breast Cancer through YAP Pathway.
Zhang Z; Luan Q; Hao W; Cui Y; Li Y; Li X
J Cancer; 2023; 14(13):2562-2573. PubMed ID: 37670970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
